This section summarizes product-specific coverage criteria and general rules that apply across listed drugs. Many products require prior authorization and coverage is provided only when the product-specific clinical criteria are met (see individual product entries). Reauthorization typically requires documentation of a positive clinical response to therapy. Examples: Adbry (dupilumab-bxxx) is covered for patients ≥12 years with moderate–severe atopic dermatitis after a trial and failure of one listed topical or systemic therapy; dosing for patients weighing <100 kg who achieve response at 16 weeks is limited to 300 mg every 4 weeks unless clinical rationale is provided (chunk 2).
Biologic and targeted immunomodulators often carry a combination-use prohibition: coverage is not provided when used concurrently with another biologic or targeted DMARD indicated for the same condition (examples: Adbry, Fasenra, Nucala, many abatacept/tofa/Rinvoq entries) — such combination use may trigger denial (chunks 2, 41, 101, 111).
Many products include indication-specific prerequisites and measurable thresholds. Examples include eosinophil-count requirements for anti‑eosinophil agents (e.g., EA initiation commonly requires ≥ 150 cells/μL), baseline diagnostic confirmation for genetic or enzyme-deficiency disorders (e.g., Rivfloza: AGXT genetic testing), and laboratory or imaging thresholds for metabolic/hepatic or bone conditions (see Nucala, Rivfloza, Praluent and Tymlos entries) (chunks 41, 139, 101, 126).
Initial coverage commonly requires documented trials of specified alternatives (step therapy) or failure/intolerance to lower-tier agents prior to approval; for some psychiatric and neurologic agents lifetime coverage is contingent on documented comparator trials (e.g., antidepressant and antipsychotic comparator lists; oral risperidone before long‑acting risperidone formulations) (chunks 216, 218, 234).
Documentation expectations: providers must submit the clinical data specified in each product entry (examples: baseline T25FW for dalfampridine, IgE and allergy testing for Xolair, genetic or enzyme testing for Opfolda and Rivfloza, BMD T‑score for teriparatide/Tymlos). Absence of required documentation or failure to meet prerequisite trial requirements may result in denial (chunks 24, 194, 109, 44, 247).
Coverage durations are product-specific but commonly set to 1 YEAR; select products have different durations (e.g., Praluent 3 years, certain osteoporosis agents 2–3 years, lifetime for some long‑acting injectables) — confirm the duration in the product entry before authorizing (chunks 2, 124, 44, 216).